Log in

iCAD Stock Forecast, Price & News

+0.95 (+8.92 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $11.60
50-Day Range
MA: $10.07
52-Week Range
Now: $11.60
Volume762,745 shs
Average Volume295,436 shs
Market Capitalization$265.65 million
P/E RatioN/A
Dividend YieldN/A
iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, such as advanced image analysis and workflow solutions in breast imaging, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Advanced Mammography Platform, a computer server residing on a customer's network that receives patient studies from the imaging modality, performs CAD and density assessment analysis, and sends the CAD results to picture archiving and communication system and/or review workstations. In addition, the company's digital mammography CAD products comprise magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves hospitals, ambulatory care centers and free standing radiation oncology facilities, and other office-based uses through sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. iCAD, Inc. has a strategic partnership agreement with Invivo Corp. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:ICAD



Sales & Book Value

Annual Sales$31.34 million
Book Value$0.26 per share


Net Income$-13,550,000.00


Market Cap$265.65 million
Next Earnings Date11/4/2020 (Estimated)
+0.95 (+8.92 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ICAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

iCAD (NASDAQ:ICAD) Frequently Asked Questions

How has iCAD's stock been impacted by COVID-19 (Coronavirus)?

iCAD's stock was trading at $11.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ICAD stock has increased by 4.3% and is now trading at $11.60.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of iCAD?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for iCAD in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for iCAD

When is iCAD's next earnings date?

iCAD is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for iCAD

How were iCAD's earnings last quarter?

iCAD Inc (NASDAQ:ICAD) issued its quarterly earnings results on Tuesday, August, 4th. The technology company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.04. The technology company had revenue of $5.57 million for the quarter. iCAD had a negative net margin of 69.88% and a negative return on equity of 75.69%.
View iCAD's earnings history

What price target have analysts set for ICAD?

4 analysts have issued 1 year price targets for iCAD's stock. Their forecasts range from $10.00 to $15.00. On average, they anticipate iCAD's share price to reach $13.50 in the next year. This suggests a possible upside of 16.4% from the stock's current price.
View analysts' price targets for iCAD

Are investors shorting iCAD?

iCAD saw a decline in short interest in the month of August. As of August 14th, there was short interest totaling 1,110,000 shares, a decline of 15.3% from the July 30th total of 1,310,000 shares. Based on an average daily trading volume, of 300,900 shares, the short-interest ratio is currently 3.7 days.
View iCAD's Short Interest

Who are some of iCAD's key competitors?

What other stocks do shareholders of iCAD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCAD investors own include Inseego (INSG), Marvell Technology Group (MRVL), NVIDIA (NVDA), JD.Com (JD), Aptiv (APTV), Advanced Micro Devices (AMD), Ambarella (AMBA), Square (SQ), Akoustis Technologies (AKTS) and InVitae (NVTA).

Who are iCAD's key executives?

iCAD's management team includes the following people:
  • Ms. Stacey M. Stevens, Pres (Age 51)
  • Mr. Michael S. Klein, Exec. Chairman & CEO (Age 65)
  • Mr. R. Scott Areglado, VP, Corp. Controller & Interim CFO (Age 55)
  • Mr. Jonathan Go, Chief Technology Officer (Age 56)
  • Ms. Annette L. Heroux, VP of Admin. (Age 62)

What is iCAD's stock symbol?

iCAD trades on the NASDAQ under the ticker symbol "ICAD."

Who are iCAD's major shareholders?

iCAD's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (2.84%), Laidlaw Wealth Management LLC (2.27%), Russell Investments Group Ltd. (1.41%), Ikarian Capital LLC (1.36%), EAM Investors LLC (1.33%) and Monashee Investment Management LLC (1.31%). Company insiders that own iCAD stock include Andy Sassine, R Scott Areglado and Stacey M Stevens.
View institutional ownership trends for iCAD

Which major investors are selling iCAD stock?

ICAD stock was sold by a variety of institutional investors in the last quarter, including EAM Investors LLC, Goldman Sachs Group Inc., Engineers Gate Manager LP, and Jane Street Group LLC. Company insiders that have sold iCAD company stock in the last year include Andy Sassine, R Scott Areglado, and Stacey M Stevens.
View insider buying and selling activity for iCAD

Which major investors are buying iCAD stock?

ICAD stock was purchased by a variety of institutional investors in the last quarter, including Laidlaw Wealth Management LLC, Federated Hermes Inc., Monashee Investment Management LLC, Russell Investments Group Ltd., Calamos Advisors LLC, Ikarian Capital LLC, Portolan Capital Management LLC, and Sturgeon Ventures LLP.
View insider buying and selling activity for iCAD

How do I buy shares of iCAD?

Shares of ICAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iCAD's stock price today?

One share of ICAD stock can currently be purchased for approximately $11.60.

How big of a company is iCAD?

iCAD has a market capitalization of $265.65 million and generates $31.34 million in revenue each year. The technology company earns $-13,550,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. iCAD employs 95 workers across the globe.

What is iCAD's official website?

The official website for iCAD is www.icadmed.com.

How can I contact iCAD?

iCAD's mailing address is 98 SPIT BROOK ROAD SUITE 100, NASHUA NH, 03062. The technology company can be reached via phone at 603-882-5200 or via email at [email protected]

This page was last updated on 9/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.